The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

SIMPLE SUMMARY: Treatment outcomes for non-small cell lung cancer (NSCLC) patients have significantly improved since the introduction of targeted therapy using tyrosine kinase inhibitors (TKI). Despite the initial promising results, most patients develop resistance due to on- or off-target mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Weiting, Kok, Klaas, Tan, Geok Wee, Meng, Pei, Mastik, Mirjam, Rifaela, Naomi, Scherpen, Frank, Hiltermann, T. Jeroen N., Groen, Harry J. M., van der Wekken, Anthonie J., van den Berg, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320221/
https://www.ncbi.nlm.nih.gov/pubmed/35884570
http://dx.doi.org/10.3390/cancers14143511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320221/
https://www.ncbi.nlm.nih.gov/pubmed/35884570
http://dx.doi.org/10.3390/cancers14143511

Ejemplares similares